Results of AGM

Roquefort Therapeutics PLC

27 June 2024

 

27 June 2024

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Results of AGM

Roquefort Therapeutics (LSE:ROQ, OTCQB: ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market, is pleased to announce that at the Company's Annual General Meeting ("AGM") held earlier today, all resolutions proposed were duly passed.

The resolutions were put to shareholders via a poll, the results of which were as follows:

Resolution		Poll Results			Total Votes Withheld*
		For	Against	Total Votes Cast
1	Shares	24,948,663	-	24,948,663	-
	%	100.00%	-
2	Shares	24,943,456	-	24,943,456	5,191
	%	100.00%	-
3	Shares	24,943,472	-	24,943,472	5,191
	%	100.00%	-
4	Shares	20,529,178	-	20,529,178	4,419,485
	%	100.00%	-
5	Shares	24,948,663	-	24,948,663	-
	%	100.00%	-
6	Shares	24,948,663	-	24,948,663	-
	%	100.00%	-
7	Shares	24,938,750	9,913	24,948,663	-
	%	99.96%	0.04%
8	Shares	24,938,730	9,933	24,948,663	-
	%	99.96%	0.04%

* Votes withheld are not counted in the calculation of the proportion of votes for and against a resolution.

The total number of ordinary shares in issue on 25 June 2024, the deadline for casting votes by proxy in advance of the AGM, was 129,149,998 shares.  19.3% of voting capital was instructed in respect of the resolutions put to the AGM.

 

Enquiries:

Roquefort Therapeutics plc	[phone]
Stephen West (Chairman) / Ajan Reginald (CEO)
SP Angel Corporate Finance LLP (Broker) Jeff Keating / David Hignell / Vadim Alexandre	[phone]
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale	[phone]
Peak IR (Investor Relations) Seb Wykeham	[phone]

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.

Roquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines.  The highly complementary profile of five best-in-class medicines consists of:

·    Midkine antibodies with significant in vivo efficacy and toxicology studies;

·    Midkine RNA therapeutics with novel anti-cancer gene editing action;

·    Midkine mRNA therapeutics with novel anti-cancer approach;

·    STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and

·    MK cell therapy with direct and NK-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).

 

END